Partner Research Award Programs

LUNGevity Foundation has been partnering with patient-led lung cancer advocacy groups—the ALK Positives and the EGFR Resisters—to support research that focuses specifically on unmet needs in the treatment of their particular types of non-small cell lung cancer (NSCLC). The ultimate goal of the research, which is selected and funded by these groups, is to transform ALK-positive lung cancer and EGFR-positive lung cancer into either chronic, manageable conditions or curable conditions.

ALK Positive/LUNGevity Lung Cancer Research Award Program

ALK Positive logoALK-positive lung cancer is a type of NSCLC in which the ALK gene is fused with, or attached to, a part of another gene. The fused gene produces a unique ALK protein that promotes abnormal, unchecked cell growth. About 5% of lung cancer patients have the ALK mutation. While there are currently five FDA-approved targeted therapies to treat ALK-positive lung cancer, the cancer inevitably recurs because the cells become resistant to the effects of the targeted therapies. Thus, there is a huge unmet need for additional treatment options for ALK-positive lung cancer patients.

ALK Positive—a group of 2,000+ ALK-positive patients and their caregivers in 42+ countries who are raising significant funds for research—and LUNGevity Foundation have partnered to support high-impact research that seeks to transform the future for patients affected by ALK-positive non-small cell lung cancer. This is the first group of ALK-positive patients to directly influence the direction of research that will, one day, save their lives.

Funded projects are expected to have a direct impact on the outcomes of patients with ALK-positive lung cancer, but innovative proposals that address other unmet needs in the ALK-positive lung cancer space are also invited for submission. Applicants are encouraged to propose projects that utilize the resources of the ALK Positive members, which include their available histories, opinions, tissues, bodily fluids, and any other aspects of their condition.

Information about the three 2020 and three 2018 ALK Positive/LUNGevity Lung Cancer Research Awardees can be found at Partner Awards.

EGFR Resisters/LUNGevity Lung Cancer Research Award Program

EGFR Resisters logoEGFR-positive lung cancer is a type of NSCLC in which the EGFR gene is mutated, promoting abnormal, unchecked cell growth. About 10%-15% of lung cancer patients have the EGFR mutation. While there are currently five FDA-approved targeted therapies to treat EGFR-positive lung cancer, the cancer inevitably recurs because the cells become resistant to the effects of the targeted therapies. Thus, there is a huge unmet need for additional treatment options for EGFR-positive lung cancer patients.

EGFR Resisters—a group of 2,000+ EGFR-positive patients and their caregivers in 70+ countries who are raising significant funds for research—and LUNGevity Foundation have partnered to support high-impact research that seeks to transform the future for patients affected by EGFR-positive non-small cell lung cancer.

A funded project is expected to have a direct impact on the outcomes of patients with EGFR-positive lung cancer, but innovative proposals that address other unmet needs in the EGFR-positive lung cancer space are also invited for submission.

Information about the 2021 EGFR Resisters/LUNGevity Lung Cancer Research Awardees will be available soon at Partner Awards.

print